The Committee for Medicinal Products for Human Use (CHMP) noted that the effectiveness of MabCampath had been demonstrated, but that there is no information from studies directly comparing MabCampath with treatment combinations including fludarabine, which are widely used to treat patients with CLL.
Inimravimite komitee jõudis otsusele, et MabCampathi kasulikkus on tõendatud, aga puudub teave uuringute kohta, kus MabCampathi võrreldaks vahetult fludarabiini sisaldavate kombinatsioonravimitega, mida laialdaselt kasutatakse kroonilise lümfotsüütleukeemiaga patsientide ravimiseks.